Komori
Occurring Fact4594BrightPath Biotherapeutics Co.,Ltd.Pharmaceuticals

Notice Regarding the Recognition of Non-Operating Income and Extraordinary Gains

During the interim accounting period of the fiscal year ending March 2027, the company recorded a ¥7,187 thousand foreign exchange gain as non-operating income and a ¥19,674 thousand gain on reversal of stock acquisition rights due to the retirement of persons eligible to receive the rights as extraordinary income.

Worth reading
46Recurring
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
26861
¥ thousand (non-operating income: ¥7,187 thousand; extraordinary income: ¥19,674 thousand)
Wording
Definitive
How definitive the wording is.

Recognition of non-operating income and extraordinary gain

Subject Entity

BrightPath Biotherapeutics Co.,Ltd.

Occurrence1 April 2026–30 September 2026 (interim accounting period of the fiscal year ending March 2027)
This disclosure11/13/2026
Cause

Generation of a foreign exchange gain and retirement of persons eligible to receive stock acquisition rights

Amount of Impact on Business Performance

Non-operating income: foreign exchange gain of ¥7,187 thousand; extraordinary income: gain on reversal of stock acquisition rights of ¥19,674 thousand

Accounting period in which recognized

Interim accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)

Impact on Earnings Forecast

For the impact of the above non-operating income and extraordinary income on financial results, please refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)" released today.

Event that occurred
ItemDetails
Event nameRecognition of non-operating income and extraordinary gain
Date of occurrence1 April 2026–30 September 2026 (interim accounting period of the fiscal year ending March 2027)
Subject EntityBrightPath Biotherapeutics Co.,Ltd.
CauseGeneration of a foreign exchange gain and retirement of persons eligible to receive stock acquisition rights
Amount of Impact on Business PerformanceNon-operating income: foreign exchange gain of ¥7,187 thousand; extraordinary income: gain on reversal of stock acquisition rights of ¥19,674 thousand
Accounting period in which recognizedInterim accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
Impact on Earnings ForecastFor the impact of the above non-operating income and extraordinary income on financial results, please refer to the "Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)" released today.
Items this document does not state (18)
Date recognized / date notice receivedTarget Locations / ProductsType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

A foreign exchange gain was generated, and a gain on reversal of stock acquisition rights was generated following the retirement of persons eligible to receive the rights.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recognition of Non-Operating Income and Extraordinary Gains | BrightPath Biotherapeutics Co.,Ltd. (4594) timely disclosure | Komori